- Home
- SIBN
SIBN
SI-BONE Inc.
as 11-21-2025 3:39pm EST
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SANTA CLARA |
| Market Cap: | 606.1M | IPO Year: | 2018 |
| Target Price: | $24.60 | AVG Volume (30 days): | 668.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.70 - $20.05 | Next Earning Date: | 11-10-2025 |
| Revenue: | $193,578,000 | Revenue Growth: | 23.27% |
| Revenue Growth (this year): | 19.94% | Revenue Growth (next year): | 16.48% |
Stock Insider Trading Activity of SI-BONE Inc. (SIBN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| FRANCIS LAURA | SIBN | Chief Executive Officer | Nov 18 '25 | Sell | $17.70 | 5,411 | $95,762.80 | 351,319 | |
| RECUPERO ANTHONY J | SIBN | President, Commercial Ops | Nov 17 '25 | Sell | $17.43 | 3,833 | $66,832.02 | 270,270 | |
| Maheshwari Anshul | SIBN | Chief Financial Officer | Nov 17 '25 | Sell | $17.42 | 3,460 | $60,297.12 | 205,073 | |
| FRANCIS LAURA | SIBN | Chief Executive Officer | Nov 17 '25 | Sell | $17.43 | 11,341 | $197,622.36 | 351,319 | |
| Pisetsky Michael A | SIBN | SVP, Ops & Adm/Chief Legal Ofr | Nov 17 '25 | Sell | $17.41 | 3,328 | $57,933.66 | 251,896 | |
| Maheshwari Anshul | SIBN | Chief Financial Officer | Nov 11 '25 | Sell | $18.33 | 2,601 | $47,684.91 | 205,073 | |
| DUNN JEFFREY W | SIBN | Director | Nov 11 '25 | Sell | $18.95 | 80,000 | $1,516,000.00 | 10,307 | |
| FRANCIS LAURA | SIBN | Chief Executive Officer | Nov 11 '25 | Sell | $17.06 | 5,411 | $92,306.79 | 351,319 | |
| DUNN JEFFREY W | SIBN | Director | Nov 3 '25 | Sell | $14.80 | 293 | $4,337.51 | 10,307 | |
| RECUPERO ANTHONY J | SIBN | President, Commercial Ops | Oct 2 '25 | Sell | $14.25 | 3,311 | $47,197.21 | 270,270 |
Latest SI-BONE Inc. News
SIBN Breaking Stock News: Dive into SIBN Ticker-Specific Updates for Smart Investing
Zacks
18 days ago
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Beats Revenue Estimates
GlobeNewswire
6 months ago
SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025
GlobeNewswire
6 months ago
SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025
Zacks
6 months ago
Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
Zacks
6 months ago
What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?
Simply Wall St.
6 months ago
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Zacks
6 months ago
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet
Simply Wall St.
7 months ago
SI-BONE First Quarter 2025 Earnings: Beats Expectations
Compare SIBN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SIBN SI-BONE Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.